About rozanolixizumab in house
Neonatal Fc receptor blocker
Used for
- Treatment of generalized myasthenia gravis in adults who are anti-AChR or anti-MuSK antibody positive.
Usual adult dose
Subcutaneous infusion once weekly for six weeks: 7 mg/kg for patients under 100 kg; 420 mg for 100 kg or more.
Common side effects
- Headache
- Infections, including respiratory infections
- Diarrhea
- Fever
Important warnings
- May increase infection risk; avoid live vaccines during treatment.
- Check for infections before starting; treatment may need delaying during serious infection.
- Can cause hypersensitivity reactions, including allergic reactions.
- May reduce immunoglobulin levels; monitor as clinically appropriate.
Pregnancy
Human pregnancy data are limited; use only when potential benefit justifies potential fetal risk.
Breastfeeding
It is unknown whether rozanolixizumab passes into human milk; effects on infants are unknown.
Interactions
- May reduce effectiveness of medicines that rely on neonatal Fc receptor recycling, including some immunoglobulin products and monoclonal antibodies.
- Avoid live vaccines during treatment; vaccine responses may be reduced.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.